Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Developmental pluripotency associated 2 (DPPA2)
- Target
- DPPA2
- Molecular classification
- Chromatin-binding protein, Epigenetic priming factor, Transcriptional regulator (by effect on chromatin accessibility, not as a classical transcription factor)
01
Overview
Developmental pluripotency associated 2 (DPPA2) is a small nuclear protein (~300 amino acids) expressed predominantly in pre-implantation embryos and germ cells. It acts as an epigenetic priming factor, binding to GC-rich promoter regions via its SAP domain and interacting with histones to regulate chromatin accessibility. DPPA2, usually as a heterodimer with DPPA4, maintains open chromatin states at developmental gene loci, preventing premature DNA methylation and facilitating proper differentiation. It is critical for zygotic genome activation and reprogramming somatic cells to pluripotency. DPPA2 expression is tightly regulated and silenced after gastrulation, and knockout studies show that its absence impairs differentiation efficiency and causes developmental defects, notably after birth. There are no approved drugs targeting DPPA2, but its role as a biomarker for pluripotency and links to cancer make it a significant molecule in stem cell biology and regenerative medicine research
- Other names
- DPPA2ECAT15-2
02
Mechanism of action
Not applicable; no drugs are known to act on DPPA2 directly
03
Biological functions
Epigenetic regulation of gene expressionPromotion of cell plasticity and pluripotencyPriming cellular differentiation by regulating bivalent chromatin and associated histone marks (H3K4me3, H3K27me3)Induction of zygotic genome activation (ZGA)Facilitating reprogramming to pluripotencyRegulation of DNA damage response and metabolic pathway shifts during reprogramming
04
Disease associations
Cancer (aberrant activation/roles documented for DPPA4, functional links for DPPA2 plausible)Primary ovarian insufficiencyAstigmatism
05
Safety considerations
Not applicable for therapeutic targeting; however, aberrant expression in cancer may contribute to malignant phenotypeMain therapeutic challenge is not relevant because DPPA2 is not a drug target
06
Biomarkers
Marker of pluripotency and early embryonic cell fateMarker for cells poised for induced pluripotency during reprogramming
Beyond the preview
Go deeper on Developmental pluripotency associated 2 (DPPA2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Developmental pluripotency associated 2 (DPPA2).